Rapt Therapeutics, Inc. (RAPT)
| Market Cap | 920.66M |
| Revenue (ttm) | 4.36M |
| Net Income (ttm) | -64.01M |
| Shares Out | 29.55M |
| EPS (ttm) | -2.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,040 |
| Open | 35.93 |
| Previous Close | 32.74 |
| Day's Range | 30.11 - 32.50 |
| 52-Week Range | 14.89 - 43.26 |
| Beta | 0.11 |
| Analysts | Buy |
| Price Target | 60.29 (+93.5%) |
| Earnings Date | Nov 15, 2021 |
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is 60.29, which is an increase of 93.49% from the latest price.
News
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
RAPT Therapeutics Reports Third Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease S...
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the ...
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...
RAPT Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...
RAPT THERAPTICS (RAPT) Reports Q2 Loss, Lags Revenue Estimates
RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -1.61% and -39.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
RAPT Therapeutics Reports Second Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for
RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to P...
SOUTH SAN FRANCISCO, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Reports Positive Data From Atopic Dermatitis Study
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
RAPT Therapeutics Raises $125M Via Equity At 6% Discount
RAPT Therapeutics Inc (NASDAQ: RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents a 6% discount from last the close price of ...
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?
RAPT Therapeutics (RAPT) has moved higher as of late, but there could definitely be trouble on the horizon for this company
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
Why RAPT Therapeutics Stock Is Surging Today
RAPT Therapeutics Inc (NASDAQ:RAPT) shares are trading higher by 95% at $36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as mono...
Why RAPT Therapeutics Stock Is Crushing It Today
The company reported great results from an early-stage study of its experimental atopic dermatitis drug.
RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100%+
RAPT Therapeutics (RAPT) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193. The post RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketi...
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
• Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once-daily oral treatment with RPT193 • Further...
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...
Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options
Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.
RAPT THERAPTICS (RAPT) Reports Q1 Loss, Misses Revenue Estimates
RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -26.92% and -28.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?